NCT05892172 is a clinical trial in Heart Failure, sponsored by Yihui Kong.

Who is sponsoring NCT05892172?

NCT05892172 is sponsored by Yihui Kong.

What condition does NCT05892172 study?

NCT05892172 studies Heart Failure.

Is NCT05892172 still recruiting?

NCT05892172 is currently status unknown. Last updated 29 June 2023.

Last reviewed 2023-06-29 · How we verify

NCT05892172

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Heart Failure and Sleep Disordered Breathing

Status unknown Last updated 29 June 2023

What this trial tests

trial in Heart Failure in 300 participants. Status unknown.

Timeline

28 June 2023

Primary endpoint
1 January 2024

30 April 2024

Quick facts

Lead sponsor	Yihui Kong
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	300
Start date	28 June 2023
Primary completion	1 January 2024
Estimated completion	30 April 2024
Sites	1 location across China

Conditions studied

Heart Failure — all drugs for Heart Failure →

Sponsor

Yihui Kong

Who can join

18 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to analyze and summarize the characteristics of arrhythmia and heart rate variability of Chinese patients with three different types of heart failure combined with sleep disordered breathing based on the clinical data, to provide new diagnosis and treatment ideas for domestic patients, and then to improve the prognosis of patients betterly.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Yihui Kong trials

Trials by the same sponsor.

NCT06070506 — Heart Failure With Improved Ejection Fraction and Deep Learning · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05892172 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yihui Kong
Last refreshed: 29 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05892172.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing